Tigecycline attenuates staphylococcal superantigen-induced T-cell proliferation and production of cytokines and chemokines

Saliba, Ranime; Paasch, Linda L.; Solh, Ali El

doi:10.1080/08923970902838672

Cited by 2 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition, in a large clinical trial for intra-abdominal infections, tigecycline and imipenem/cilastatin had similar efficacies but there was an increased incidence of postsurgical wound infections with tigecycline (7). Although the reason for these observations is unclear, tigecycline is known to induce immunosuppressive effects by decreasing cytokines and chemokines in vitro and in vivo (39,40). Thus, the decreased efficacy of tigecycline in the tissue may relate to its immunomodulatory effects, which are more likely to contribute to host defense against bacteria in tissue than bacteria in a biofilm on an implant.…”

Section: Discussionmentioning

confidence: 99%

Daptomycin and Tigecycline Have Broader Effective Dose Ranges than Vancomycin as Prophylaxis against a Staphylococcus aureus Surgical Implant Infection in Mice

Niska

Shahbazian

Ramos

et al. 2012

Antimicrob Agents Chemother

View full text Add to dashboard Cite

Vancomycin is widely used for intravenous prophylaxis against surgical implant infections. However, it is unclear whether alternative antibiotics used to treat methicillin-resistant Staphylococcus aureus (MRSA) infections are effective as prophylactic agents. The aim of this study was to compare the efficacies of vancomycin, daptomycin, and tigecycline as prophylactic therapy against a methicillin-sensitive S. aureus (MSSA) or MRSA surgical implant infection in mice. MSSA or MRSA was inoculated into the knee joints of mice in the presence of a surgically placed medical-grade metallic implant. The efficacies of low-versus high-dose vancomycin (10 versus 110 mg/kg), daptomycin (1 versus 10 mg/kg), and tigecycline (1 versus 10 mg/kg) intravenous prophylaxis were compared using in vivo bioluminescence imaging, ex vivo bacterial counts, and biofilm formation. High-dose vancomycin, daptomycin, and tigecycline resulted in similar reductions in bacterial burden and biofilm formation. In contrast, low-dose daptomycin and tigecycline were more effective than low-dose vancomycin against the implant infection. In this mouse model of surgical implant MSSA or MRSA infection, daptomycin and tigecycline prophylaxis were effective over a broader dosage range than vancomycin. Future studies in humans will be required to determine whether these broader effective dose ranges for daptomycin and tigecycline in mice translate to improved efficacy in preventing surgical implant infections in clinical practice.

show abstract

Section: Discussionmentioning

confidence: 99%

Daptomycin and Tigecycline Have Broader Effective Dose Ranges than Vancomycin as Prophylaxis against a Staphylococcus aureus Surgical Implant Infection in Mice

Niska

Shahbazian

Ramos

et al. 2012

Antimicrob Agents Chemother

View full text Add to dashboard Cite

show abstract

“…Theoretically, low serum levels of tigecycline with the present recommended dosage may be a problem in treating Salmonella bacteremia. Therefore, the potential limitation of tigecycline therapy for human Salmonella infections must be considered when treating Salmonella bloodstream infections (18,24,25). In the view of the obvious differences in pharmacokinetic profiles between mice and humans, the extrapolation of animal studies to clinical situations should be further verified.…”

mentioning

confidence: 99%

In Vitro and In Vivo Intracellular Killing Effects of Tigecycline against Clinical Nontyphoid Salmonella Isolates Using Ceftriaxone as a Comparator

Tang¹,

Ko²,

Chen³

et al. 2011

Antimicrob Agents Chemother

View full text Add to dashboard Cite

Salmonella is an important, worldwide food-borne pathogen. Resistance to fluoroquinolones and cephalosporins has been increasingly reported, and new therapeutic agents are desperately needed. In this study, we evaluated the in vitro antimicrobial susceptibility of clinical nontyphoidal Salmonella isolates to tigecycline. Antibacterial activity of tigecycline, ceftriaxone, and ciprofloxacin were investigated by time-kill studies and the murine peritonitis model. The MIC 50 /MIC 90 values of tigecycline, ceftriaxone, and ciprofloxacin against 76 Salmonella isolates were 0.25/0.5, 1/8, and 0.125/0.5 g/ml, respectively. The intracellular inhibitory activity of tigecycline at 0.5 g/ml (1؋ MIC) against Salmonella isolates in human peripheral blood mononuclear cells was sustained for 24 h. In a mouse peritonitis model, tigecycline reduced the extracellular and intracellular bacterial counts from 10 7 CFU/ml and 10 5 CFU/ml, respectively, to an undetectable level within 96 h. The results were similar to those obtained with ceftriaxone. The survival rate of mice exposed to tigecycline after being infected by an inoculum of 1 ؋ 10 5 CFU was 80%, and that of mice exposed to ceftriaxone was 100%. When the inoculum was increased to 1.3 ؋ 10 6 CFU, the survival rate of mice treated by tigecycline was 20%, and that of mice exposed to ceftriaxone was 0% (P ‫؍‬ 0.2). When a ceftriaxone-and ciprofloxacin-resistant but tigecycline-susceptible isolate was tested, mice treated by tigecycline had a higher survival rate than those treated by ceftriaxone (15/20 [75%] versus 6/20 [30%]; P ‫؍‬ 0.011). Our results suggest that tigecycline is at least as effective as ceftriaxone for murine Salmonella infections and warrants further clinical investigations to delineate its potential against human Salmonella infections.

show abstract

Tigecycline attenuates staphylococcal superantigen-induced T-cell proliferation and production of cytokines and chemokines

Cited by 2 publications

References 0 publications

Daptomycin and Tigecycline Have Broader Effective Dose Ranges than Vancomycin as Prophylaxis against a Staphylococcus aureus Surgical Implant Infection in Mice

Daptomycin and Tigecycline Have Broader Effective Dose Ranges than Vancomycin as Prophylaxis against a Staphylococcus aureus Surgical Implant Infection in Mice

In Vitro and In Vivo Intracellular Killing Effects of Tigecycline against Clinical Nontyphoid Salmonella Isolates Using Ceftriaxone as a Comparator

Contact Info

Product

Resources

About